New Research on ImmunoPrecise Antibodies Ltd (IPA-NASDAQ/IPA-TSX)

Posted by Karen Goldfarb

May 18, 2022 at 11:06 AM

An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download ImmunoPrecise Antibodies Ltd Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)

New Research Released on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

March 10, 2022 at 12:14 PM

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download FSD Pharma Inc.  Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, multiple sclerosis, inflammatory, MS, major depressive disorder (MDD), myelin degradation, bipilar disorder

New Research Released on Emerald Health Pharmaceuticals (CLOSELY-HELD)

Posted by Karen Goldfarb

November 30, 2021 at 6:22 PM

An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Emerald Health Pharmaceuticals Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic